Triton Market Research presents their Global Alzheimer’s disease therapeutics and diagnostics in Healthcare market report, segmented on the basis of Therapeutics (marketed, branded, generic and pipeline drugs), Disease stage (late, middle and early stage), Diagnostics (Lumbar puncture test, positron emission tomography, electroencephalography, magnetic resonance imaging, computed tomography and other diagnostics), and by Geography (North America, The United States, Canada, Latin America, Asia Pacific, Middle East and Africa.
The report discusses industry value chain analysis, Porter's 5 Force Analysis, drivers, restraints, vendor profiles, global market size, forecasts & analysis (2019-2027).
Triton Market Research expects the global Alzheimer’s disease therapeutics and diagnostics in the healthcare market to witness a compound annual growth rate (CAGR) of 7.78% during the forecast period of 2019-2027. The main reason for dementia among the old population is Alzheimer’s disease, and therefore, the increasing geriatric population plays the key driver for global Alzheimer’s disease therapeutics and diagnostics market. As older people opt for affordable and inexpensive diagnostics and treatment, the global market growth is expected to rise drastically.
The North America region has acquired a significant share in the Alzheimer’s disease therapeutics and diagnostics in the healthcare market. Triton Market Research forecasts that the North America region will continue to relish the advantage throughout the projected years (2019-2027). Substantial growth in the healthcare expenditure would be witnessed by Asia Pacific in comparison to other regions such as North America, Europe, the Middle East, and Africa. Moreover, the global healthcare expenditure is likely to grow tremendously by 2040, and more use of diagnostics and treatment procedures for the Alzheimer’s disease is expected by the patients, thus boosting the market globally. Asia Pacific was the second-highest contributor in the global Alzheimer’s disease therapeutics and diagnostics in the healthcare market in 2018.
In its market analysis report, Triton Market Research has highlighted prominent market players like AbbVie Inc, Voyager Therapeutics, Amarantus BioScience Holdings, Inc., Axon Neuroscience SE, Baxter International Inc. Biogen, Cognoptix, Inc, Diagenic ASA, Roche ltd., GE Healthcare, Merck and Co. Inc., Pfizer, Piramal Enterprises Ltd., Siemen Medical Solutions Inc., and Sun Pharmaceuticals Industries Ltd.
The global Alzheimer’s disease therapeutics and diagnostics in the healthcare market is fragmented due to the presence of many international, regional, and local vendors. Thus, several markets are adopting strategies like mergers and acquisitions to maintain their hold in the global market. For instance, AbbVie Inc. signed a collaboration agreement with Voyager Therapeutics for developing a new therapy for Alzheimer's disease and other neurodegenerative conditions.
The main objective of this collaboration was to develop a potential one-time treatment to reduce tau pathology by the delivery of an AAV vector antibody to the brain. This collaboration provided an opportunity to the company to upgrade its product portfolio and increase its neuroscience revenue. On the same front, many other companies are collaborating with regional and local organizations to expand their presence in the global Alzheimer’s disease therapeutics and diagnostics in healthcare market.
The Global Wood Based Panel Market is estimated to witness growth with a CAGR of 6..
The Global Sport Utility Vehicle (SUV) Market is estimated to grow with a CAGR of ..
The global market for cosmetic bioactive ingredients is expected to advance at a C..